A Clinical Study to Investigate the Safety and Immunogenicity in Relation to Product Attributes of mRNA-1083 (Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2] and Influenza Vaccine)
Public ClinicalTrials.gov record NCT06508320. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Observer-blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity in Relation to the Product Attributes of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Adults ≥50 to <65 Years of Age
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety, reactogenicity, and immunogenicity in relation to the product attributes of mRNA-1083 vaccine when administered as a single intramuscular (IM) injection in adults ≥50 to \<65 years of age.
Study identification
- NCT ID
- NCT06508320
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 931 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 64 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 15, 2024 (Actual)
- Primary completion
- Sep 25, 2025 (Actual)
- Completion
- Sep 25, 2025 (Actual)
- Last update posted
- Oct 8, 2026
2024 – 2025
United States locations
- U.S. sites
- 12
- U.S. states
- 7
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Indago Research & Health Center, Inc. | Hialeah | Florida | 33012 | — |
| Cenexel RCA | Hollywood | Florida | 33024 | — |
| Suncoast Research Group, LLC DBA Flourish Research | Miami | Florida | 33135 | — |
| Cenexel IRA | Decatur | Georgia | 30030 | — |
| DM Clinical Research - River Forest | River Forest | Illinois | 60305 | — |
| JCCT | Lenexa | Kansas | 66219 | — |
| Hassman Research Institute - Berlin - CenExel - PPDS | Marlton | New Jersey | 80530 | — |
| DM Clinical Research - Philadelphia | Philadelphia | Pennsylvania | 19107 | — |
| DM Clinical Research - Cyfair Clinical Research Center - PPDS | Houston | Texas | 77065-5685 | — |
| Clinical Trials of Texas, LLC DBA Flourish Research | San Antonio | Texas | 78229 | — |
| DM Clinical Research - Sugarland | Sugar Land | Texas | 77478 | — |
| DM Clinical Research - Tomball MDC | Tomball | Texas | 77375 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06508320, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 8, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06508320 live on ClinicalTrials.gov.